Published in J Am Coll Surg on May 01, 2007
The Effect of ERAS on Pancreaticoduodenectomy (ERAS) | NCT02372331
Outcomes following pancreatic resection: variability among high-volume providers. Surgery (2008) 1.73
Readmission after pancreatectomy for pancreatic cancer in Medicare patients. J Gastrointest Surg (2009) 1.66
Fast-track concepts in major open upper abdominal and thoracoabdominal surgery: a review. World J Surg (2011) 1.55
Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies. J Am Coll Surg (2012) 1.55
Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. World J Surg (2013) 1.13
Systematic review and meta-analysis of enhanced recovery after pancreatic surgery with particular emphasis on pancreaticoduodenectomies. World J Surg (2013) 1.07
What is the effect of age on pancreatic resection? Adv Surg (2009) 1.06
Fast-track programmes for hepatopancreatic resections: where do we stand? HPB (Oxford) (2011) 1.01
Fast-track surgery: procedure-specific aspects and future direction. Langenbecks Arch Surg (2012) 0.99
Impact of clinical pathways in surgery. Langenbecks Arch Surg (2008) 0.98
Enhanced recovery after pancreatic surgery: a systematic review of the evidence. HPB (Oxford) (2014) 0.93
Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality. J Am Geriatr Soc (2011) 0.89
Update on the management of pancreatic cancer: surgery is not enough. World J Gastroenterol (2015) 0.89
Pancreaticoduodenectomy for pancreatic cancer: the Verona experience. Surg Today (2011) 0.85
Is there a learning curve for pancreaticoduodenectomy after fellowship training? HPB Surg (2011) 0.85
Implementation of an enhanced recovery programme following pancreaticoduodenectomy. HPB (Oxford) (2012) 0.84
The impact of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction on pancreatic fistula after pancreaticoduodenectomy: meta-analysis of randomized controlled trials. HPB (Oxford) (2014) 0.82
Enhanced recovery after surgery pathway in patients undergoing pancreaticoduodenectomy. World J Surg (2014) 0.80
Hospital-level resource use by the oldest-old for pancreaticoduodenectomy at high-volume hospitals. Surgery (2015) 0.80
Enhanced Recovery After Surgery Program in Patients Undergoing Pancreaticoduodenectomy: A PRISMA-Compliant Systematic Review and Meta-Analysis. Medicine (Baltimore) (2016) 0.80
Pancreatic cancer surgery and nutrition management: a review of the current literature. Hepatobiliary Surg Nutr (2015) 0.79
A 6-day clinical pathway after a pancreaticoduodenectomy is feasible, safe and efficient. HPB (Oxford) (2012) 0.79
Adherence to ERAS elements in major visceral surgery-an observational pilot study. Langenbecks Arch Surg (2016) 0.77
Outcomes Improvement Is Not Continuous Along the Learning Curve for Pancreaticoduodenectomy at the Hospital Level. J Gastrointest Surg (2015) 0.77
Early oral feeding after pancreatoduodenectomy enhances recovery without increasing morbidity. HPB (Oxford) (2013) 0.77
Perioperative care with fast-track management in patients undergoing pancreaticoduodenectomy. World J Surg (2014) 0.77
Anaesthetic perioperative management of patients with pancreatic cancer. World J Gastroenterol (2014) 0.75
Impact of critical pathway implementation on hospital stay and costs in patients undergoing pancreaticoduodenectomy. Korean J Hepatobiliary Pancreat Surg (2014) 0.75
Enhanced recovery pathways in pancreatic surgery: State of the art. World J Gastroenterol (2016) 0.75
Safety of an Enhanced Recovery Pathway for Patients Undergoing Open Hepatic Resection. PLoS One (2016) 0.75
Racial and Socioeconomic Differences Manifest in Process Measure Adherence for Enhanced Recovery After Surgery Pathway. Dis Colon Rectum (2017) 0.75
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery (2007) 6.62
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg (2002) 6.24
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery (2007) 4.72
From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol (2007) 3.87
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery (2007) 3.42
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg (2007) 3.38
Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg (2006) 3.35
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
LigAmp for sensitive detection of single-nucleotide differences. Nat Methods (2004) 2.70
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63
Surgical management of bile duct injuries sustained during laparoscopic cholecystectomy: perioperative results in 200 patients. Ann Surg (2005) 2.58
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res (2003) 2.49
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol (2002) 2.44
Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula. J Gastrointest Surg (2004) 2.35
Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res (2003) 2.35
Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations. Am J Pathol (2002) 2.35
DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res (2006) 2.29
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol (2002) 2.22
Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation (2010) 2.20
Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? Am J Surg Pathol (2003) 2.20
MUC4 expression increases progressively in pancreatic intraepithelial neoplasia. Am J Clin Pathol (2002) 2.18
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res (2006) 2.13
Major bile duct injuries associated with laparoscopic cholecystectomy: effect of surgical repair on quality of life. Ann Surg (2002) 2.09
Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery (2006) 2.07
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Mod Pathol (2005) 2.03
Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol (2002) 1.96
Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res (2004) 1.93
Pancreatic cancer. Curr Probl Cancer (2002) 1.92
Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice. Cancer Biol Ther (2003) 1.88
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle (2009) 1.87
Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther (2008) 1.85
Resected serous cystic neoplasms of the pancreas: a review of 158 patients with recommendations for treatment. J Gastrointest Surg (2007) 1.83
Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol Ther (2005) 1.83
Does fibrin glue sealant decrease the rate of pancreatic fistula after pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg (2004) 1.81
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2004) 1.76
Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab (2002) 1.76
Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol (2002) 1.75
Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res (2004) 1.74
Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther (2004) 1.74
Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther (2008) 1.74
Hospital readmission after pancreaticoduodenectomy. J Gastrointest Surg (2006) 1.73
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68
Pancreaticoduodenectomy in the very elderly. J Gastrointest Surg (2006) 1.67
Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis. Ann Surg (2003) 1.66
Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial. J Gastrointest Surg (2006) 1.65
Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res (2004) 1.63
Cumulative operative experience is decreasing during general surgery residency: a worrisome trend for surgical trainees? J Am Coll Surg (2008) 1.63
The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther (2004) 1.63
Almost all infiltrating colloid carcinomas of the pancreas and periampullary region arise from in situ papillary neoplasms: a study of 39 cases. Am J Surg Pathol (2002) 1.59
Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Res (2003) 1.58
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol (2012) 1.55
Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol (2002) 1.53
Defining treatment and outcomes of hepaticojejunostomy failure following pancreaticoduodenectomy. J Gastrointest Surg (2013) 1.51
Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol (2002) 1.50
T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes. EMBO J (2007) 1.47
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma--part 3: update on 5-year survival. J Gastrointest Surg (2005) 1.46
Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl (2003) 1.43
Have endovascular procedures negatively impacted general surgery training? Ann Surg (2007) 1.42
Wasting lives: the effects of toxic waste exposure on health. The case of Campania, Southern Italy. Cancer Biol Ther (2011) 1.42
Gangliocytic paraganglioma: case report and review of the literature. J Gastrointest Surg (2007) 1.42
Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res (2004) 1.41
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res (2009) 1.41
Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Pathol (2004) 1.40
Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg (2005) 1.39
Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol (2002) 1.39
A new technique for successful management of a complete suprahepatic caval transection. J Am Coll Surg (2007) 1.38
Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res (2004) 1.37
Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. Ann Surg (2006) 1.36
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One (2012) 1.35
Primary cystic neoplasms of the pancreas. Neoplastic disorders of emerging importance-current state-of-the-art and unanswered questions. J Gastrointest Surg (2003) 1.35
Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg (2004) 1.34
Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. Am J Surg Pathol (2004) 1.33
Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Clin Cancer Res (2004) 1.32
Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology (2002) 1.32
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys (2007) 1.31
Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res (2007) 1.31